Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Research & Development: 2009-2024

Historic Research & Development for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $16.7 million.

  • Heron Therapeutics' Research & Development fell 22.28% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 44.33%. This contributed to the annual value of $16.7 million for FY2024, which is 57.37% down from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Research & Development is $16.7 million, which was down 57.37% from $39.1 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Research & Development ranged from a high of $174.5 million in FY2020 and a low of $16.7 million during FY2024.
  • In the last 3 years, Heron Therapeutics' Research & Development had a median value of $39.1 million in 2023 and averaged $46.2 million.
  • In the last 5 years, Heron Therapeutics' Research & Development grew by 4.27% in 2020 and then crashed by 57.37% in 2024.
  • Yearly analysis of 5 years shows Heron Therapeutics' Research & Development stood at $174.5 million in 2020, then dropped by 25.05% to $130.8 million in 2021, then plummeted by 36.78% to $82.7 million in 2022, then tumbled by 52.68% to $39.1 million in 2023, then slumped by 57.37% to $16.7 million in 2024.